FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* COVINO GREGORY F						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]									of Reportin cable) or (give title	g Pers	on(s) to Issi 10% Ow Other (s	/ner	
(Last) BIOGEN 225 BIN	•	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/22/2018									below) VP, Chief Account			·	
(Street) CAMBR (City)			02142 (Zip)		_ 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								e) X Form : Form :	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Oity)	(3	•		n Dori				ioo A 6	au irad	Die		f or Do	noficial	lly Owns					
Date			2. Transa Date	Transaction ate			2A. Deemed Execution Date,			4. Securit	ies Acquire Of (D) (Inst	d (A) or	5. Amor Securiti	unt of es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			(IIIsu. 4)	
Common Stock 02/22/				/2018	3			М		194	A	\$0	4,73	4,738.3601		D			
Common	Common Stock 02/22/				/2018	2018			F		58	D	\$284.	31 4,68	4,680.3601		D		
		7	able II -								osed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code (8)		n of		6. Date E Expiratio (Month/D	n Dat	Amount of		f s g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	i G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	\$0	02/22/2018			M			194	(1)	\Box	02/22/2019	Common Stock	194	\$0	402		D		
Restricted	\$0	02/22/2018			J			100(2)	(1)		02/22/2019	Common	100	\$0	302		D		

Explanation of Responses:

1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

2. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

/s/ Suzanne Murray, Attorney in Fact for Gregory F. Covino

02/26/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.